Robocath achieves positive results in R-Evolution multicenter European clinical study on robotic coronary angioplasty
Carthera’s SonoCloud technology demonstrates safety and therapeutic potential in clinical trial on patients living with Alzheimer’s Disease
AACR 2022: Tollys releases new preclinical data demonstrating lifelong potent anti-tumor immunity of TL-532
Human Cell Design launches Endoc-BH5, an advanced human beta cell model enabling new discoveries in type 1 and 2 diabetes research
Tollys accelerates development of TLR3 agonist candidates for intravenous administration in immuno-oncology
Tollys accelerates development of TLR3 agonist candidates for intravenous administration in immuno-oncology
Robocath concludes first European clinical study to demonstrate safety and efficacy of robotic coronary angioplasty performed with R-One
Study results will be presented at EuroPCR conference in Paris, France, May 2022
PDC*line Pharma opens last cohort of PDC-LUNG-101 clinical trial
B2 cohort (high dose added to anti-PD-1) of the PDC-LUNG-101 trial with PDC*lung01 therapeutic cancer vaccine candidate for non-small cell lung cancer has been opened and first patients were dosed
CARTHERA’S SonoCloud technology enhances the efficacy of immunotherapies for the treatment of brain tumors
Low Intensity Pulsed Ultrasound device can enhance delivery of CAR-T therapies and penetration of checkpoint inhibitors into the brain of preclinical glioma models; increasing probability of long-lasting immunity
REGEnLIFE presents first results of pilot clinical trial evaluating photobiomodulation technology in the treatment of Alzheimer’s disease
• Within treated patient group, trends showed improved cognitive and executive functions, improved language comprehension and verbal memory, in comparison to placebo group
• REGEnLIFE’s technology shown to be safe and well-tolerated by patients
• Initial results open up new possibilities for development of brain-gut stimulation device for prevention and treatment of neurodegenerative diseases